Cargando…
Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants—A Potential Novel Biomarker of Disease Activity
Background: In chronic inflammatory demyelinating polyneuropathy (CIDP), there is an urgent need for biomarkers to monitor ongoing disease activity. Serum calprotectin (CLP) induces signaling pathways involved in inflammatory processes and has been shown to correlate with markers of disease activity...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473624/ https://www.ncbi.nlm.nih.gov/pubmed/34589050 http://dx.doi.org/10.3389/fneur.2021.723009 |
_version_ | 1784575030101803008 |
---|---|
author | Stascheit, Frauke Hotter, Benjamin Klose, Sarah Meisel, Christian Meisel, Andreas Klehmet, Juliane |
author_facet | Stascheit, Frauke Hotter, Benjamin Klose, Sarah Meisel, Christian Meisel, Andreas Klehmet, Juliane |
author_sort | Stascheit, Frauke |
collection | PubMed |
description | Background: In chronic inflammatory demyelinating polyneuropathy (CIDP), there is an urgent need for biomarkers to monitor ongoing disease activity. Serum calprotectin (CLP) induces signaling pathways involved in inflammatory processes and has been shown to correlate with markers of disease activity in other autoimmune disorders. Thus, we wanted to study the potential value of CLP in comparison to serum neurofilament light chain (sNfl) to monitor disease activity. Materials and Methods: Sera from 63 typical and atypical CIDP and 6 MMN patients with varying degrees of disease activity were analyzed in comparison with 40 healthy controls (HC) in a cross-sectional design. Association of CLP and sNfl levels with socio-demographics, disease duration, CIDP disease activity scale (CDAS), and impairment status [medical research council-sum score (MRC-SS), the inflammatory neuropathy cause and treatment disability score (INCAT-DS), grip strength, and maximum walking distance], patient-reported outcome (PRO) parameters [SF-36 questionnaire, Beck's depression index (BDI), and fatigue severity scale (FSS)], as well as treatment regime were investigated using uni- and multivariate analysis. Results: CLP and sNfl levels were significantly higher in all CIDP patients compared to HC (p = 0.0009). Multivariate analysis adjusted for age and gender revealed that CLP acts as an independent predictor for CIDP and MMN. CLP was significantly associated with active disease course according to CDAS and correlated with MRC-SS, whereas sNfl correlated with parameters of disease impairment. There was no correlation with PRO, except for sNfl and the mental health composite score. Subgroup analysis revealed no differences between typical CIDP and atypical variants. Conclusions: CLP was elevated in CIDP and variants and was associated with active disease course, whereas sNfl shows further potential as biomarker of axonal degeneration. Thus, CLP might be a suitable additive biomarker for measurement of ongoing inflammation, which is greatly needed to guide better patient care in CIDP. |
format | Online Article Text |
id | pubmed-8473624 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84736242021-09-28 Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants—A Potential Novel Biomarker of Disease Activity Stascheit, Frauke Hotter, Benjamin Klose, Sarah Meisel, Christian Meisel, Andreas Klehmet, Juliane Front Neurol Neurology Background: In chronic inflammatory demyelinating polyneuropathy (CIDP), there is an urgent need for biomarkers to monitor ongoing disease activity. Serum calprotectin (CLP) induces signaling pathways involved in inflammatory processes and has been shown to correlate with markers of disease activity in other autoimmune disorders. Thus, we wanted to study the potential value of CLP in comparison to serum neurofilament light chain (sNfl) to monitor disease activity. Materials and Methods: Sera from 63 typical and atypical CIDP and 6 MMN patients with varying degrees of disease activity were analyzed in comparison with 40 healthy controls (HC) in a cross-sectional design. Association of CLP and sNfl levels with socio-demographics, disease duration, CIDP disease activity scale (CDAS), and impairment status [medical research council-sum score (MRC-SS), the inflammatory neuropathy cause and treatment disability score (INCAT-DS), grip strength, and maximum walking distance], patient-reported outcome (PRO) parameters [SF-36 questionnaire, Beck's depression index (BDI), and fatigue severity scale (FSS)], as well as treatment regime were investigated using uni- and multivariate analysis. Results: CLP and sNfl levels were significantly higher in all CIDP patients compared to HC (p = 0.0009). Multivariate analysis adjusted for age and gender revealed that CLP acts as an independent predictor for CIDP and MMN. CLP was significantly associated with active disease course according to CDAS and correlated with MRC-SS, whereas sNfl correlated with parameters of disease impairment. There was no correlation with PRO, except for sNfl and the mental health composite score. Subgroup analysis revealed no differences between typical CIDP and atypical variants. Conclusions: CLP was elevated in CIDP and variants and was associated with active disease course, whereas sNfl shows further potential as biomarker of axonal degeneration. Thus, CLP might be a suitable additive biomarker for measurement of ongoing inflammation, which is greatly needed to guide better patient care in CIDP. Frontiers Media S.A. 2021-09-13 /pmc/articles/PMC8473624/ /pubmed/34589050 http://dx.doi.org/10.3389/fneur.2021.723009 Text en Copyright © 2021 Stascheit, Hotter, Klose, Meisel, Meisel and Klehmet. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Stascheit, Frauke Hotter, Benjamin Klose, Sarah Meisel, Christian Meisel, Andreas Klehmet, Juliane Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants—A Potential Novel Biomarker of Disease Activity |
title | Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants—A Potential Novel Biomarker of Disease Activity |
title_full | Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants—A Potential Novel Biomarker of Disease Activity |
title_fullStr | Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants—A Potential Novel Biomarker of Disease Activity |
title_full_unstemmed | Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants—A Potential Novel Biomarker of Disease Activity |
title_short | Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants—A Potential Novel Biomarker of Disease Activity |
title_sort | calprotectin in chronic inflammatory demyelinating polyneuropathy and variants—a potential novel biomarker of disease activity |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473624/ https://www.ncbi.nlm.nih.gov/pubmed/34589050 http://dx.doi.org/10.3389/fneur.2021.723009 |
work_keys_str_mv | AT stascheitfrauke calprotectininchronicinflammatorydemyelinatingpolyneuropathyandvariantsapotentialnovelbiomarkerofdiseaseactivity AT hotterbenjamin calprotectininchronicinflammatorydemyelinatingpolyneuropathyandvariantsapotentialnovelbiomarkerofdiseaseactivity AT klosesarah calprotectininchronicinflammatorydemyelinatingpolyneuropathyandvariantsapotentialnovelbiomarkerofdiseaseactivity AT meiselchristian calprotectininchronicinflammatorydemyelinatingpolyneuropathyandvariantsapotentialnovelbiomarkerofdiseaseactivity AT meiselandreas calprotectininchronicinflammatorydemyelinatingpolyneuropathyandvariantsapotentialnovelbiomarkerofdiseaseactivity AT klehmetjuliane calprotectininchronicinflammatorydemyelinatingpolyneuropathyandvariantsapotentialnovelbiomarkerofdiseaseactivity |